drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified CAR T cells targeting B7-H3 (CD276) with an inducible caspase-9 safety switch; designed to kill B7-H3–positive tumor cells and allow on-demand elimination of the cells if needed.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting B7-H3 (CD276). Antigen engagement triggers T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity to kill B7-H3–positive tumor cells. Incorporates an inducible caspase-9 safety switch for on-demand elimination of the CAR-T cells.
drug_name
iC9-CAR.B7-H3 T Cell Therapy
nct_id_drug_ref
NCT06347068